Home > Quotes > FRX

Forest Laboratories, Inc. Stock Quote & Summary Data

FRX 
$37.91
*  
0.07
  negative  
0.18%
Get FRX Alerts
*Delayed - data as of May 21, 2013 13:13 ET 
Exchange: NYSE
Industry: Consumer Durables
Community Rating:
View:    FRX Real Time
 
 

Symbol List Views

Stock Details

CHARTS

COMPANY NEWS

STOCK ANALYSIS

FUNDAMENTALS

HOLDINGS

Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.


Don't know the stock symbol? Use the symbol lookup tool.

Alphabetize the sort order of my symbols 
Symbol Lookup
Log in or Register
 Save stocks for next time
 | Sponsored

1 Year Target: 37
Today's High/Low:  / 
Share Volume:
90 Day Avg. Daily Volume This is the average share volume for the past 50 trading days, for NASDAQ stocks and 90 trading days for Non-NASDAQ stocks. This field allows you to compare today’s trading to the average daily volume. 1,518,730
Previous Close: $ 37.98
52 Week High /Low: $ 39.09 / $ 31.28
Market cap “Market Capitalization” is a measure of the estimated value of the common equity securities of the company or their equivalent. It does not include securities convertible into the common equity securities. “Market Capitalization” is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable). NASDAQ does not use this value to determine compliance with the listing requirements. 10,094,835,766
P/E Ratio: NE
Forward P/E(1y) A widely used stock evaluation measure. For a security, the Price/Earnings Ratio is given by dividing the Last Sale Price by the Average EPS (Earnings Per Share) Estimate for the specified fiscal time period. The forward P/E refers to the value for the next full year. 42.20
Earnings Per Share (EPS) The EPS listed on our infoquote and Summary Quote page is "12-mos Rolling". EPS represents the portion of a company's profit allocated to each outstanding share of common stock. Net income (reported or estimated) for a period of time is divided by the total number of shares outstanding (TSO) during that period; See growth rate measures for EPS. Our vendor's methodology for the EPS on the infoquote and Summary Quote pages follows the EPS used by the majority of the analysts following the stock, in many cases this is EBITDA EPS. $ -0.12
Annualized dividend N/A
Ex Dividend Date N/A
Dividend Payment Date N/A
Current Yield 0 %
Beta 0.97

 Intraday Chart

5d | 1m | 6m | 12m | More Charting

ETFs with FRX as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
4.26% SPDR S&P Pharmaceuticals ETF (XPH) +2.06  (3.44%)

We make it easy to follow the leaders. PowerShares QQQ. 100 companies at the top of innovation in one fund.


*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.

**Green highlights the top performing ETF by % change in the past 100 days.

 Company Description (as filed with the SEC)

Forest Laboratories, Inc. and its subsidiaries (the Company or Forest) develop, manufacture and sell branded forms of ethical drug products most of which require a physician's prescription. Our most important United States products are marketed directly, or “detailed,” to physicians by our salesforces. We emphasize detailing to physicians of those branded ethical drugs which we believe have the most potential for growth and benefit to patients. We also focus on the development and introduction of new products, including products developed in collaboration with licensing partners. Our products include those developed by us and those acquired from other pharmaceutical companies and integrated into our marketing and distribution systems. We are a Delaware corporation organized in 1956, and our principal executive offices are located at 909 Third Avenue, New York, New York 10022 (telephone number 212-421-7850). Our corporate website address is http://www.frx.com.  ... More ...  



News Headlines for FRX

Forest to Present Aclidinium Bromide and Roflumilast Clinical Data at the American Thoracic Society (ATS) International Conference
5/17/2013 8:08:00 AM - Business Wire
Forest Laboratories, Inc. to Present Data from Cariprazine and Levomilnacipran Phase 3 Trials at American Psychiatric Association Annual Meeting
5/16/2013 8:00:00 AM - Business Wire
Forest-Trevena Ink Deal - Analyst Blog
5/14/2013 12:06:12 PM - Zacks.com
Ironwood and Forest to Present Linaclotide Data at Digestive Disease Week® 2013
5/14/2013 8:00:00 AM - Business Wire
Analysts' Actions: MU BSX CVC FRX
5/10/2013 8:45:00 AM - TheStreet
 

Consensus Recommendation